Footnotes

• Competing interests MT, MB and JR were members of the NICE Guideline Development Group (GDG) tasked with writing NICE Guideline CG140. The National Collaborating Centre for Cancer was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary; MB has received honorariums for lectures from Cephalon and Grünenthal in the past three years but not during the period when the guideline was being developed; there were no other relationships or activities that could appear to have influenced the submitted work.

• Provenance and peer review Not commissioned; internally peer reviewed.

• Correction notice This article has been corrected since it was published Online First. The following sections have been updated for grammatical purposes: 'The National Institute for Health and Clinical Excellence (NICE) issued guideline in May 2012,' now reads 'The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012,'; 'While NICE guideline would not usually recommend doses,' now reads 'While NICE guidelines would not usually recommend doses,'; and the phrase 'to give inexperienced practitioners faced with a prescribing decision clearer guideline.' now reads 'to give inexperienced practitioners faced with a prescribing decision clearer guidance.'